<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-07458R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Genetics and Genomics/Genomics</subject><subject>Diabetes and Endocrinology/Type 2 Diabetes</subject><subject>Nephrology/Chronic Kidney Disease</subject></subj-group></article-categories><title-group><article-title>Common Variants of Inflammatory Cytokine Genes Are Associated with Risk of Nephropathy in Type 2 Diabetes among Asian Indians</article-title><alt-title alt-title-type="running-head">Cytokine Gene Variants in DN</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahluwalia</surname><given-names>Tarunveer Singh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Khullar</surname><given-names>Madhu</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ahuja</surname><given-names>Monica</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kohli</surname><given-names>Harbir Singh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bhansali</surname><given-names>Anil</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mohan</surname><given-names>Viswanathan</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Venkatesan</surname><given-names>Radha</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rai</surname><given-names>Taranjit Singh</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sud</surname><given-names>Kamal</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Singal</surname><given-names>Pawan K.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research, Chandigarh, India</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Madras Diabetes Research Foundation and Dr. Mohan's Diabetes Specialties Centre, Gopalapuram, Chennai, India</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Institute of Cardiovascular Sciences, St Boniface General Hospital Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Toland</surname><given-names>Amanda Ewart</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Ohio State University Medical Center, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>madhu.khullar@gmail.com</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: TSA MK HSK DAB KS. Performed the experiments: TSA MA TSR. Analyzed the data: TSA. Contributed reagents/materials/analysis tools: MK VM RV PKS. Wrote the paper: TSA MK VM RV PKS.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>9</day><month>4</month><year>2009</year></pub-date><volume>4</volume><issue>4</issue><elocation-id>e5168</elocation-id><history><date date-type="received"><day>24</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>12</day><month>3</month><year>2009</year></date></history><copyright-statement>Ahluwalia et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>Inflammatory cytokine genes have been proposed as good candidate genes for conferring susceptibility to diabetic nephropathy. In the present study, we examined the combined effect of multiple alleles of pro inflammatory cytokine genes for determining the risk of nephropathy in type 2 diabetic patients.</p></sec><sec><title>Methodology/Principal Findings</title><p>Eight single nucleotide polymorphisms (SNPs) of pro-inflammatory cytokine genes (<italic>CCL2</italic>, <italic>TGFB1</italic>, <italic>IL8, CCR5,</italic> and <italic>MMP9</italic>) were genotyped in two independently ascertained type 2 diabetic cohorts with (DN) and without nephropathy (DM); consisting of patients from North India (n&#x0200a;&#x0003d;&#x0200a;495) and South India (n&#x0200a;&#x0003d;&#x0200a;188). Genotyping was carried out using PCR, allele specific oligonucleotide-PCR (ASO-PCR), PCR-RFLP and TaqMan allelic discrimination assays and the gene&#x02013;gene interaction among genetic variants were determined by multi dimensional reduction (MDR) software. Serum high sensitive CRP (hs-CRP) levels were measured by ELISA. The hs-CRP levels were significantly higher in DN as compared to the DM group (p&#x0003c;0.05). The <italic>CCL2</italic>, <italic>IL8</italic>, <italic>CCR5</italic> and <italic>MMP9</italic> polymorphisms were found to be associated with the risk of diabetic nephropathy. Frequency of <italic>CCL2</italic> II, <italic>IL8</italic> -251AA, <italic>CCR5</italic> 59029AA and MMP9 279Gln/Gln genotypes were significantly higher in DN than in DM group (p&#x0003c;0.05) and associated with an increased risk of nephropathy in both North and South Indian cohorts. <italic>CCR5</italic> DD and <italic>IL8</italic> -251AA genotypes were more prevalent in North Indian DN group only. The co-occurrence of risk associated genotypes (II, -2518GG (<italic>CCL2</italic>), DD (<italic>CCR5</italic>) and 279Gln/Gln (<italic>MMP9</italic>) conferred a tenfold increased risk of nephropathy among type 2 diabetics (p&#x0003c;0.0002).</p></sec><sec><title>Conclusion</title><p>The present study highlights that common variants of inflammatory cytokine genes exert a modest effect on risk of DN and a combination of risk alleles confer a substantial increased risk of nephropathy in type 2 diabetes among Asian Indians.</p></sec></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Genetic susceptibility plays an important role in the pathogenesis of diabetic nephropathy (DN) and multiple genetic approaches, including candidate gene association studies and the genome-wide association study (GWAS) are being pursued to identify the susceptibility gene(s) for DN <xref ref-type="bibr" rid="pone.0005168-Greene1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005168-Prasad2">&#x0005b;7&#x0005d;</xref>. In recent years, it has become evident that inflammatory mechanisms contribute significantly to the development and progression of DN. These include the infiltration of renal compartments by lymphocytes and monocytes/macrophages as well as local production of cytokines and chemokines in the kidney <xref ref-type="bibr" rid="pone.0005168-Ruster1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005168-NavarroGonzalez1">&#x0005b;9&#x0005d;</xref>. Although the mechanisms underlying the regulation of these cytokines in the kidneys of patients with diabetes mellitus remain unclear, it has been proposed that genetic variations in the genes encoding the inflammatory cytokines might confer susceptibility to DN <xref ref-type="bibr" rid="pone.0005168-Maeda2">&#x0005b;10&#x0005d;</xref> by altering their functions or expressions. For example, a promoter polymorphism (-2518A/G) in the <italic>CCL2</italic> gene was found to be associated with progressive kidney failure in Koreans with type 2 diabetes <xref ref-type="bibr" rid="pone.0005168-Moon1">&#x0005b;11&#x0005d;</xref> and <italic>TGFB1</italic> T869C gene polymorphism showed association with nephropathy in type 2 diabetic Chinese patients <xref ref-type="bibr" rid="pone.0005168-Wong1">&#x0005b;12&#x0005d;</xref>. Polymorphisms in the <italic>CCR5</italic> and <italic>MMP9</italic> have been also reported to be associated with the increased risk of nephropathy <xref ref-type="bibr" rid="pone.0005168-Hirakawa1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005168-Maeda3">&#x0005b;13&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005168-Nakajima1">&#x0005b;15&#x0005d;</xref>. In a polygenic complex disorder like DN, association of individual polymorphisms in genes may be small and sometimes non-informative, whereas specific combinations of specific genotypes may be more relevant. However, few studies have examined the multiple alleles simultaneously for determining the risk of DN <xref ref-type="bibr" rid="pone.0005168-Ahluwalia2">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005168-Jacobsen1">&#x0005b;17&#x0005d;</xref>. In the present study, we investigated combinatorial polymorphisms among five inflammatory genes (<italic>TGFB1:</italic> T869C (Leu10Pro) and Tyr81His; <italic>CCL2</italic>: A-2518G and Insertion/Deletion (I/D); <italic>CCR5</italic>: Insertion/Deletion (I/D) and G59029A; <italic>IL8</italic>: T-251A; <italic>MMP9</italic>: Arg279Gln (G&#x0003e;A)) for association with the risk of susceptibility to diabetic nephropathy.</p></sec><sec id="s2"><title>Results</title><p>Demographic and clinical characteristics of the subjects enrolled in the study are given in <xref ref-type="table" rid="pone-0005168-t001">Table 1</xref>. The mean duration of type 2 diabetes (considered with respect to date of detection of diabetes) was similar in diabetic nephropathy and diabetes without nephropathy group (DM) (16 vs.15 years). Percent frequency of retinopathy was higher in DN (76.2&#x00025;) as compared to DM (37.7&#x00025;) group.</p><table-wrap id="pone-0005168-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005168.t001</object-id><label>Table 1</label><caption><title>Demographic profile of type 2 diabetes subjects (with &#x00026; without) nephropathy among North India and South India.</title></caption><graphic id="pone-0005168-t001-1" xlink:href="pone.0005168.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005168-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="4" align="left" rowspan="1">North Indian Cohorts</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Type 2 diabetes subjects</td><td align="left" rowspan="1" colspan="1">a vs b</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">With nephropathy<xref ref-type="table-fn" rid="nt102">a</xref> (n&#x0200a;&#x0003d;&#x0200a;240)</td><td align="left" rowspan="1" colspan="1">Without nephropathy<xref ref-type="table-fn" rid="nt103">b</xref> (n&#x0200a;&#x0003d;&#x0200a;255)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age (years)</bold></td><td align="left" rowspan="1" colspan="1">60.12&#x000b1;6.2</td><td align="left" rowspan="1" colspan="1">58.1&#x000b1;8.0</td><td align="left" rowspan="1" colspan="1">0.32<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Males/Females (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">94/146 (39/61)</td><td align="left" rowspan="1" colspan="1">105/150 (41/59)</td><td align="left" rowspan="1" colspan="1">1.0<xref ref-type="table-fn" rid="nt106">e</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Mean duration of diabetes (years)</bold></td><td align="left" rowspan="1" colspan="1">16.3&#x000b1;3.3</td><td align="left" rowspan="1" colspan="1">15.62&#x000b1;5.25</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Mean arterial S.B.P. (mmHg)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">145.4&#x000b1;22.5</td><td align="left" rowspan="1" colspan="1">135.08&#x000b1;17.7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt104">c</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Mean arterial D.B.P. (mmHg)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">88.8&#x000b1;10.2</td><td align="left" rowspan="1" colspan="1">84.21&#x000b1;7.51</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt104">c</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BMI (Kg/m<sup>2</sup>)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">27.8&#x000b1;2.9</td><td align="left" rowspan="1" colspan="1">23.95&#x000b1;2.95</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt104">c</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>hs-CRP (mg/L)</bold></td><td align="left" rowspan="1" colspan="1">2.65&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">1.89&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>S. Creatinine (mg&#x00025;)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">4.22&#x000b1;2.07</td><td align="left" rowspan="1" colspan="1">1.14&#x000b1;0.11</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Blood Urea (mg&#x00025;)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">106.7&#x000b1;46.2</td><td align="left" rowspan="1" colspan="1">36.2&#x000b1;15.2</td><td align="left" rowspan="1" colspan="1">0.00<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Random blood sugar (mg/dl)</bold></td><td align="left" rowspan="1" colspan="1">182.7&#x000b1;53.5</td><td align="left" rowspan="1" colspan="1">181.3&#x000b1;56.5</td><td align="left" rowspan="1" colspan="1">0.78<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Total cholesterol (130&#x02013;250 mg&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">255.3&#x000b1;64.1</td><td align="left" rowspan="1" colspan="1">259.24&#x000b1;63.7</td><td align="left" rowspan="1" colspan="1">0.88<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Tryglycerides (mg&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">204.8&#x000b1;39.2</td><td align="left" rowspan="1" colspan="1">207.6&#x000b1;38.2</td><td align="left" rowspan="1" colspan="1">0.85<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>HDL (mg&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">63.5&#x000b1;15.1</td><td align="left" rowspan="1" colspan="1">61.05&#x000b1;16.08</td><td align="left" rowspan="1" colspan="1">0.75<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Retinopathy (&#x00025;)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">76.2</td><td align="left" rowspan="1" colspan="1">37.7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05<xref ref-type="table-fn" rid="nt106">e</xref></td></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0005168-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="4" align="left" rowspan="1">South Indian Cohorts</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">With nephropathy<xref ref-type="table-fn" rid="nt102">a</xref> (n&#x0200a;&#x0003d;&#x0200a;96)</td><td align="left" rowspan="1" colspan="1">Without nephropathy<xref ref-type="table-fn" rid="nt103">b</xref> (n&#x0200a;&#x0003d;&#x0200a;92)</td><td align="left" rowspan="1" colspan="1">a vs b</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age (years)</bold></td><td align="left" rowspan="1" colspan="1">60.5&#x000b1;8.7</td><td align="left" rowspan="1" colspan="1">53.5&#x000b1;12.1</td><td align="left" rowspan="1" colspan="1">0.08<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Males/Females (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">53/43 (55/45)</td><td align="left" rowspan="1" colspan="1">47/45 (51/49)</td><td align="left" rowspan="1" colspan="1">0.97<xref ref-type="table-fn" rid="nt106">e</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Mean duration of diabetes (years)</bold></td><td align="left" rowspan="1" colspan="1">17.4&#x000b1;7</td><td align="left" rowspan="1" colspan="1">13.0&#x000b1;2.8</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Mean arterial S.B.P. (mmHg)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">143.5&#x000b1;20.5</td><td align="left" rowspan="1" colspan="1">127.4&#x000b1;17.6</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt104">c</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Mean arterial D.B.P. (mmHg)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">85.1&#x000b1;10.5</td><td align="left" rowspan="1" colspan="1">77.2&#x000b1;12.2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt104">c</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BMI (Kg/m<sup>2</sup>)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">24.5&#x000b1;3.7</td><td align="left" rowspan="1" colspan="1">25.8&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1">0.06<xref ref-type="table-fn" rid="nt104">c</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>S. Creatinine (mg&#x00025;)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">5.5&#x000b1;1.3</td><td align="left" rowspan="1" colspan="1">1.0&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Blood Urea (mg&#x00025;)</bold><xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">64&#x000b1;18.8</td><td align="left" rowspan="1" colspan="1">22.5&#x000b1;5.8</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Fasting blood sugar (mg/dl)</bold></td><td align="left" rowspan="1" colspan="1">173&#x000b1;69</td><td align="left" rowspan="1" colspan="1">161&#x000b1;59</td><td align="left" rowspan="1" colspan="1">0.15<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Total cholesterol (130&#x02013;250 mg&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">176&#x000b1;74</td><td align="left" rowspan="1" colspan="1">192&#x000b1;37</td><td align="left" rowspan="1" colspan="1">0.26<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Tryglycerides (mg&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">175&#x000b1;88</td><td align="left" rowspan="1" colspan="1">165&#x000b1;84</td><td align="left" rowspan="1" colspan="1">0.23<xref ref-type="table-fn" rid="nt105">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>HDL (mg&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">43&#x000b1;10</td><td align="left" rowspan="1" colspan="1">44&#x000b1;10</td><td align="left" rowspan="1" colspan="1">0.97<xref ref-type="table-fn" rid="nt105">d</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>p&#x0003c;0.05; Values are mean&#x000b1;standard deviation.</p></fn><fn id="nt102"><label>a</label><p>Type 2 diabetic with nephropathy.</p></fn><fn id="nt103"><label>b</label><p>Type 2 diabetic without nephropathy.</p></fn><fn id="nt104"><label>c</label><p>Mann-Whitney <italic>U</italic> test.</p></fn><fn id="nt105"><label>d</label><p>Student's <italic>t</italic>-test.</p></fn><fn id="nt106"><label>e</label><p>Pearson's Chi square test.</p></fn></table-wrap-foot></table-wrap><sec id="s2a"><title>High sensitivity- C Reactive Protein (hs-CRP) levels</title><p>The mean plasma hs-CRP levels were significantly higher in cases (2.65&#x000b1;1.2 mg/L; p&#x0003c;0.05) as compared to controls (1.89&#x000b1;1.1 mg/L) (<xref ref-type="table" rid="pone-0005168-t001">Table 1</xref>). hs-CRP levels were not associated with any particular genotype within the case or control groups as per logistic regression analysis and <italic>t</italic>-test performed (data not shown).</p></sec><sec id="s2b"><title>Genetic Analysis (North Indian Cohort)</title><p>All the polymorphisms examined in this study were in Hardy-Weinberg equilibrium in both set of populations. Allele and genotype frequencies of the polymorphisms of the <italic>TGFB1</italic>, <italic>CCL2</italic>, <italic>IL8</italic>, <italic>CCR5</italic>, and <italic>MMP9</italic> genes are given in <xref ref-type="table" rid="pone-0005168-t002">Table 2</xref>. The genotype frequencies were different between DN and DM groups. Five of the eight variant alleles showed significantly higher allele frequency (<italic>CCL2</italic> Insertion (I): p&#x0003c;0.0001; <italic>IL8</italic> -251A: p&#x0003c;0.007; <italic>CCR5</italic> Deletion (D): p&#x0003c;0.0001, <italic>CCR5</italic> 59029A: p&#x0003c;0.0001; <italic>MMP9</italic> 279Gln: p&#x0003c;0.0001) in DN as compared to DM group. When genotypes were stratified according to dominant and recessive models, after the multiple logistic regression analysis (<xref ref-type="fig" rid="pone-0005168-g001">Figure 1</xref>, and <xref ref-type="fig" rid="pone-0005168-g002">2</xref>), five genotypes (Insertion/Insertion (II) of <italic>CCL2</italic>; AA of <italic>IL8</italic>; Deletion/Deletion (DD) and 59029AA of <italic>CCR5</italic>; and AA of <italic>MMP9</italic>) showed significant association with high risk of DN (p&#x0003c;0.05), whereas three genotypes (Deletion/Deletion (DD) of <italic>CCL2</italic>; Insertion/Insertion (II) of <italic>CCR5</italic>; and Arg/Arg of <italic>MMP9</italic>) showed significant association with decreased risk of DN (p&#x0003c;0.05). None of the covariates (age, sex, duration of diabetes, and blood pressure) except blood urea and serum creatinine (p&#x0003c;0.05) were found to be associated with the DN (data not shown).</p><fig id="pone-0005168-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005168.g001</object-id><label>Figure 1</label><caption><title>Univariate logistic regression analysis in type 2 diabetic patients with <italic>TGFB1</italic> 869 (T&#x0003e;C), <italic>CCL2</italic> -2518 (A&#x0003e;G), <italic>CCL2</italic> (Del.&#x0003e;Ins.), <italic>IL8</italic> -251 (T&#x0003e;A), <italic>CCR5</italic> Del 32 (Ins.&#x0003e;Del.), and <italic>MMP9</italic> Arg279Gln (G&#x0003e;A) polymorphisms as independent and diabetic nephropathy as a dependent variable among North Indian Cohort.</title><p>&#x0002a;p&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0005168.g001"/></fig><fig id="pone-0005168-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005168.g002</object-id><label>Figure 2</label><caption><title>Multivariate logistic regression analysis in type 2 diabetic patients with <italic>TGFB1</italic> 869 (T&#x0003e;C), <italic>CCL2</italic> -2518 (A&#x0003e;G), <italic>CCL2</italic> (Del.&#x0003e;Ins.), <italic>IL8</italic> -251 (T&#x0003e;A), <italic>CCR5</italic> Del 32 (Ins.&#x0003e;Del.), and <italic>MMP9</italic> Arg279Gln (G&#x0003e;A) polymorphisms as independent and diabetic nephropathy as a dependent variable among North Indian Cohort.</title><p>&#x0002a;p&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0005168.g002"/></fig><table-wrap id="pone-0005168-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005168.t002</object-id><label>Table 2</label><caption><title>Allele and genotype frequencies of the inflammatory gene SNPs in North and South Indians.</title></caption><graphic id="pone-0005168-t002-2" xlink:href="pone.0005168.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005168-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="5" align="left" rowspan="1">North Indians</td></tr><tr><td align="left" rowspan="1" colspan="1">Polymorphisms</td><td colspan="2" align="left" rowspan="1">Allele Frequency</td><td align="left" rowspan="1" colspan="1">OR(95&#x00025;CI)</td><td align="left" rowspan="1" colspan="1">p value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DM (2n&#x0200a;&#x0003d;&#x0200a;510)</td><td align="left" rowspan="1" colspan="1">DN (2n&#x0200a;&#x0003d;&#x0200a;480)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold><italic>TGFB1</italic></bold><bold>: rs1800470</bold></td><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;362 (0.71)</td><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;331 (0.69)</td><td align="left" rowspan="1" colspan="1">1.1 (0.83&#x02013;1.44)</td><td align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>869 T&#x0003e;C (Leu10Pro)</bold></td><td align="left" rowspan="1" colspan="1">C&#x0200a;&#x0003d;&#x0200a;148 (0.29)</td><td align="left" rowspan="1" colspan="1">C&#x0200a;&#x0003d;&#x0200a;149 (0.31)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TGFB1</bold></td><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;497 (0.975)</td><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;466 (0.97)</td><td align="left" rowspan="1" colspan="1">1.14 (0.53&#x02013;2.46)</td><td align="left" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Tyr81His (T&#x0003e;C)</bold></td><td align="left" rowspan="1" colspan="1">C&#x0200a;&#x0003d;&#x0200a;13 (0.025)</td><td align="left" rowspan="1" colspan="1">C&#x0200a;&#x0003d;&#x0200a;14 (0.03)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCL2</italic></bold><bold>: rs1024611</bold></td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;342 (0.67)</td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;317 (0.66)</td><td align="left" rowspan="1" colspan="1">1.04 (0.8&#x02013;1.36)</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>-2518 A&#x0003e;G</bold></td><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;168 (0.33)</td><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;163 (0.34)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCL2</italic></bold><bold>: rs3917887</bold><xref ref-type="table-fn" rid="nt107">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">I&#x0200a;&#x0003d;&#x0200a;250 (0.49)</td><td align="left" rowspan="1" colspan="1">I&#x0200a;&#x0003d;&#x0200a;326 (0.68)</td><td align="left" rowspan="1" colspan="1">2.03 (1.57&#x02013;2.63)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ins./Del. (D&#x0003e;I)</bold></td><td align="left" rowspan="1" colspan="1">D&#x0200a;&#x0003d;&#x0200a;260 (0.51)</td><td align="left" rowspan="1" colspan="1">D&#x0200a;&#x0003d;&#x0200a;154 (0.32)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>IL8</italic></bold><bold>: rs4073</bold><xref ref-type="table-fn" rid="nt107">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;362 (0.71)</td><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;302 (0.63)</td><td align="left" rowspan="1" colspan="1">1.44 (1.1&#x02013;1.88)</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>-251 T&#x0003e;A</bold></td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;148 (0.29)</td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;178 (0.37)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCR5</italic></bold><bold>: Del 32</bold><xref ref-type="table-fn" rid="nt107">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">I&#x0200a;&#x0003d;&#x0200a;250 (0.49)</td><td align="left" rowspan="1" colspan="1">I&#x0200a;&#x0003d;&#x0200a;130 (0.27)</td><td align="left" rowspan="1" colspan="1">2.58 (1.98&#x02013;3.37)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ins./Del.(I&#x0003e;D)</bold></td><td align="left" rowspan="1" colspan="1">D&#x0200a;&#x0003d;&#x0200a;260 (0.51)</td><td align="left" rowspan="1" colspan="1">D&#x0200a;&#x0003d;&#x0200a;350 (0.73)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCR5</italic></bold><bold>: 59029 G&#x0003e;A</bold><xref ref-type="table-fn" rid="nt107">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;260 (0.51)</td><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;153 (0.32)</td><td align="left" rowspan="1" colspan="1">2.22 (1.71&#x02013;2.87)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;250 (0.49)</td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;327(0.68)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>MMP9: rs17576</bold><xref ref-type="table-fn" rid="nt107">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;342 (0.67)</td><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;254 (0.53)</td><td align="left" rowspan="1" colspan="1">1.81 (1.40&#x02013;2.34)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>(Arg279Gln) G&#x0003e;A</bold></td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;168 (0.33)</td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;226 (0.47)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0005168-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Polymorphisms</td><td colspan="2" align="left" rowspan="1">Genotype Frequency</td><td align="left" rowspan="1" colspan="1">p value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DM (n&#x0200a;&#x0003d;&#x0200a;255)</td><td align="left" rowspan="1" colspan="1">DN (n&#x0200a;&#x0003d;&#x0200a;240)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold><italic>TGFB1</italic></bold><bold>: rs1800470</bold></td><td align="left" rowspan="1" colspan="1">TT&#x0200a;&#x0003d;&#x0200a;144 (0.565)</td><td align="left" rowspan="1" colspan="1">TT&#x0200a;&#x0003d;&#x0200a;144 (0.60)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>869 T&#x0003e;C (Leu10Pro)</bold></td><td align="left" rowspan="1" colspan="1">TC<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;74 (0.29)</td><td align="left" rowspan="1" colspan="1">TC&#x0200a;&#x0003d;&#x0200a;41 (0.17)</td><td align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC&#x0200a;&#x0003d;&#x0200a;37 (0.145)</td><td align="left" rowspan="1" colspan="1">CC&#x0200a;&#x0003d;&#x0200a;55 (0.23)</td><td align="left" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>TGFB1</italic></bold><bold>: Tyr81His (T&#x0003e;C)</bold></td><td align="left" rowspan="1" colspan="1">TT&#x0200a;&#x0003d;&#x0200a;242 (0.95)</td><td align="left" rowspan="1" colspan="1">TT&#x0200a;&#x0003d;&#x0200a;226(0.94)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TC&#x0200a;&#x0003d;&#x0200a;13 (0.05)</td><td align="left" rowspan="1" colspan="1">TC&#x0200a;&#x0003d;&#x0200a;14 (0.06)</td><td align="left" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC&#x0200a;&#x0003d;&#x0200a;0 (0)</td><td align="left" rowspan="1" colspan="1">CC&#x0200a;&#x0003d;&#x0200a;0 (0)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCL2</italic></bold><bold>: rs1024611</bold></td><td align="left" rowspan="1" colspan="1">AA&#x0200a;&#x0003d;&#x0200a;122 (0.48)</td><td align="left" rowspan="1" colspan="1">AA&#x0200a;&#x0003d;&#x0200a;94 (0.39)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>-2518 A&#x0003e;G</bold></td><td align="left" rowspan="1" colspan="1">AG<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;97 (0.38)</td><td align="left" rowspan="1" colspan="1">AG&#x0200a;&#x0003d;&#x0200a;130(0.54)</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GG&#x0200a;&#x0003d;&#x0200a;36 (0.14)</td><td align="left" rowspan="1" colspan="1">GG&#x0200a;&#x0003d;&#x0200a;16 (0.07)</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCL2</italic></bold><bold>: rs3917887</bold></td><td align="left" rowspan="1" colspan="1">DD&#x0200a;&#x0003d;&#x0200a;89 (0.35)</td><td align="left" rowspan="1" colspan="1">DD&#x0200a;&#x0003d;&#x0200a;36 (0.15)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ins./Del. (D&#x0003e;I)</bold></td><td align="left" rowspan="1" colspan="1">ID<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;82 (0.32)</td><td align="left" rowspan="1" colspan="1">ID&#x0200a;&#x0003d;&#x0200a;79 (0.33)</td><td align="left" rowspan="1" colspan="1">0.0005</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">II<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;84 (0.33)</td><td align="left" rowspan="1" colspan="1">II&#x0200a;&#x0003d;&#x0200a;125 (0.52)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>IL8</italic></bold><bold>: rs4073</bold></td><td align="left" rowspan="1" colspan="1">TT&#x0200a;&#x0003d;&#x0200a;130 (0.51)</td><td align="left" rowspan="1" colspan="1">TT&#x0200a;&#x0003d;&#x0200a;103(0.43)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>-251 T&#x0003e;A</bold></td><td align="left" rowspan="1" colspan="1">TA&#x0200a;&#x0003d;&#x0200a;107 (0.42)</td><td align="left" rowspan="1" colspan="1">TA&#x0200a;&#x0003d;&#x0200a;96 (0.40)</td><td align="left" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;18 (0.07)</td><td align="left" rowspan="1" colspan="1">AA&#x0200a;&#x0003d;&#x0200a;41 (0.17)</td><td align="left" rowspan="1" colspan="1">0.0005</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCR5</italic></bold><bold>: Del 32</bold></td><td align="left" rowspan="1" colspan="1">II&#x0200a;&#x0003d;&#x0200a;94 (0.37)</td><td align="left" rowspan="1" colspan="1">II&#x0200a;&#x0003d;&#x0200a;50 (0.21)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ins./Del. (I&#x0003e;D)</bold></td><td align="left" rowspan="1" colspan="1">ID&#x0200a;&#x0003d;&#x0200a;64 (0.25)</td><td align="left" rowspan="1" colspan="1">ID&#x0200a;&#x0003d;&#x0200a;29 (0.12)</td><td align="left" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DD<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;97 (0.38)</td><td align="left" rowspan="1" colspan="1">DD&#x0200a;&#x0003d;&#x0200a;161(0.67)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCR5</italic></bold><bold>: 59029 G&#x0003e;A</bold></td><td align="left" rowspan="1" colspan="1">GG&#x0200a;&#x0003d;&#x0200a;90 (0.35)</td><td align="left" rowspan="1" colspan="1">GG&#x0200a;&#x0003d;&#x0200a;40 (0.16)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GA&#x0200a;&#x0003d;&#x0200a;80 (0.31)</td><td align="left" rowspan="1" colspan="1">GA&#x0200a;&#x0003d;&#x0200a;75 (0.31)</td><td align="left" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;85 (0.34)</td><td align="left" rowspan="1" colspan="1">AA&#x0200a;&#x0003d;&#x0200a;125 (0.52)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>MMP9</italic></bold><bold>: rs17576</bold></td><td align="left" rowspan="1" colspan="1">GG&#x0200a;&#x0003d;&#x0200a;122(0.48)</td><td align="left" rowspan="1" colspan="1">GG&#x0200a;&#x0003d;&#x0200a;72(0.30)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>(Arg 279 Gln) G&#x0003e;A</bold></td><td align="left" rowspan="1" colspan="1">GA<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;97 (0.38)</td><td align="left" rowspan="1" colspan="1">GA&#x0200a;&#x0003d;&#x0200a;113(0.47)</td><td align="left" rowspan="1" colspan="1">0.0007</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;36 (0.14)</td><td align="left" rowspan="1" colspan="1">AA&#x0200a;&#x0003d;&#x0200a;55 (0.23)</td><td align="left" rowspan="1" colspan="1">0.0002</td></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0005168-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="5" align="left" rowspan="1">South Indians</td></tr><tr><td align="left" rowspan="1" colspan="1">Polymorphisms</td><td colspan="2" align="left" rowspan="1">Allele Frequency</td><td align="left" rowspan="1" colspan="1">OR(95&#x00025;CI)</td><td align="left" rowspan="1" colspan="1">p value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DM (2n&#x0200a;&#x0003d;&#x0200a;184)</td><td align="left" rowspan="1" colspan="1">DN (2n&#x0200a;&#x0003d;&#x0200a;192)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCL2</italic></bold><bold>: rs3917887</bold><xref ref-type="table-fn" rid="nt107">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">I&#x0200a;&#x0003d;&#x0200a;92 (0.5)</td><td align="left" rowspan="1" colspan="1">I&#x0200a;&#x0003d;&#x0200a;121 (0.63)</td><td align="left" rowspan="1" colspan="1">1.7 (1.12&#x02013;2.57)</td><td align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ins./Del. (D&#x0003e;I)</bold></td><td align="left" rowspan="1" colspan="1">D&#x0200a;&#x0003d;&#x0200a;92 (0.5)</td><td align="left" rowspan="1" colspan="1">D&#x0200a;&#x0003d;&#x0200a;71 (0.37)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>IL8</italic></bold><bold>: rs4073</bold></td><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;134 (0.73)</td><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;123 (0.64)</td><td align="left" rowspan="1" colspan="1">1.5 (0.96&#x02013;2.33)</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>-251 T&#x0003e;A</bold></td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;50 (0.27)</td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;69 (0.36)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCR5</italic></bold><bold>: Del 32</bold></td><td align="left" rowspan="1" colspan="1">I&#x0200a;&#x0003d;&#x0200a;151 (0.82)</td><td align="left" rowspan="1" colspan="1">I&#x0200a;&#x0003d;&#x0200a;161 (0.84)</td><td align="left" rowspan="1" colspan="1">0.88 (0.51&#x02013;1.5)</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ins./Del.(I&#x0003e;D)</bold></td><td align="left" rowspan="1" colspan="1">D&#x0200a;&#x0003d;&#x0200a;33 (0.18)</td><td align="left" rowspan="1" colspan="1">D&#x0200a;&#x0003d;&#x0200a;31 (0.16)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCR5</italic></bold><bold>: 59029 G&#x0003e;A</bold><xref ref-type="table-fn" rid="nt107">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;99 (0.54)</td><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;67 (0.35)</td><td align="left" rowspan="1" colspan="1">2.17 (1.43&#x02013;3.29)</td><td align="left" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;85 (0.46)</td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;125 (0.65)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>MMP9</italic></bold><bold>: rs17576</bold><xref ref-type="table-fn" rid="nt107">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;116 (0.63)</td><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;84 (0.44)</td><td align="left" rowspan="1" colspan="1">2.19 (2.45&#x02013;3.31)</td><td align="left" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>(Arg 279 Gln) G&#x0003e;A</bold></td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;68 (0.37)</td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;108 (0.56)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0005168-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Polymorphisms</td><td colspan="2" align="left" rowspan="1">Genotype Frequency</td><td align="left" rowspan="1" colspan="1">p value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DM (n&#x0200a;&#x0003d;&#x0200a;92)</td><td align="left" rowspan="1" colspan="1">DN (n&#x0200a;&#x0003d;&#x0200a;96)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>CCL2</italic>: rs3917887</td><td align="left" rowspan="1" colspan="1">DD&#x0200a;&#x0003d;&#x0200a;29 (0.32)</td><td align="left" rowspan="1" colspan="1">DD&#x0200a;&#x0003d;&#x0200a;20 (0.21)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ins./Del. (D&#x0003e;I)</td><td align="left" rowspan="1" colspan="1">ID&#x0200a;&#x0003d;&#x0200a;34 (0.36)</td><td align="left" rowspan="1" colspan="1">ID&#x0200a;&#x0003d;&#x0200a;32 (0.33)</td><td align="left" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">II<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;29 (0.32)</td><td align="left" rowspan="1" colspan="1">II&#x0200a;&#x0003d;&#x0200a;44 (0.46)</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>IL8</italic>: rs4073</td><td align="left" rowspan="1" colspan="1">TT&#x0200a;&#x0003d;&#x0200a;58 (0.63)</td><td align="left" rowspan="1" colspan="1">TT&#x0200a;&#x0003d;&#x0200a;36 (0.38)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">-251 T&#x0003e;A</td><td align="left" rowspan="1" colspan="1">TA<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;19 (0.21)</td><td align="left" rowspan="1" colspan="1">TA&#x0200a;&#x0003d;&#x0200a;51 (0.53)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA&#x0200a;&#x0003d;&#x0200a;15 (0.16)</td><td align="left" rowspan="1" colspan="1">AA&#x0200a;&#x0003d;&#x0200a;9 (0.09)</td><td align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>CCR5</italic>: Del 32</td><td align="left" rowspan="1" colspan="1">II&#x0200a;&#x0003d;&#x0200a;64 (0.69)</td><td align="left" rowspan="1" colspan="1">II&#x0200a;&#x0003d;&#x0200a;69 (0.72)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ins./Del. (I&#x0003e;D)</td><td align="left" rowspan="1" colspan="1">ID&#x0200a;&#x0003d;&#x0200a;23 (0.26)</td><td align="left" rowspan="1" colspan="1">ID&#x0200a;&#x0003d;&#x0200a;23 (0.24)</td><td align="left" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DD&#x0200a;&#x0003d;&#x0200a;5 (0.05)</td><td align="left" rowspan="1" colspan="1">DD&#x0200a;&#x0003d;&#x0200a;4 (0.04)</td><td align="left" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>CCR5</italic>: 59029 G&#x0003e;A</td><td align="left" rowspan="1" colspan="1">GG&#x0200a;&#x0003d;&#x0200a;35 (0.38)</td><td align="left" rowspan="1" colspan="1">GG&#x0200a;&#x0003d;&#x0200a;20 (0.21)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GA&#x0200a;&#x0003d;&#x0200a;30 (0.33)</td><td align="left" rowspan="1" colspan="1">GA&#x0200a;&#x0003d;&#x0200a;28 (0.29)</td><td align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;27 (0.29)</td><td align="left" rowspan="1" colspan="1">AA&#x0200a;&#x0003d;&#x0200a;48 (0.50)</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>MMP9</italic>: rs17576</td><td align="left" rowspan="1" colspan="1">GG&#x0200a;&#x0003d;&#x0200a;42 (0.46)</td><td align="left" rowspan="1" colspan="1">GG&#x0200a;&#x0003d;&#x0200a;28 (0.29)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">(Arg 279 Gln) G&#x0003e;A</td><td align="left" rowspan="1" colspan="1">GA&#x0200a;&#x0003d;&#x0200a;31 (0.34)</td><td align="left" rowspan="1" colspan="1">GA&#x0200a;&#x0003d;&#x0200a;29 (0.30)</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;19 (0.20)</td><td align="left" rowspan="1" colspan="1">AA&#x0200a;&#x0003d;&#x0200a;39 (0.41)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn id="nt107"><label>&#x0002a;</label><p>p&#x0003c;0.05; Genotype frequency calculation is with respect to the homozygous wild type genotypes in each group.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Genetic analysis (South Indian cohort)</title><p><xref ref-type="fig" rid="pone-0005168-g003">Figure 3</xref> shows the mutant allele frequency comparison between of north Indian and south Indian subjects. The Dominant/Recessive models after logistic regression analysis are shown in <xref ref-type="fig" rid="pone-0005168-g004">figures 4</xref> and <xref ref-type="fig" rid="pone-0005168-g005">5</xref>. No significant differences in either genotype or allele frequencies were observed between the two groups, except for <italic>CCR5</italic> I/D polymorphism; minor allele frequency (MAF) was higher in north Indians as compared to South Indians.</p><fig id="pone-0005168-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005168.g003</object-id><label>Figure 3</label><caption><title>Genotype frequency comparison between Asian type 2 diabetic North Indians (ANI), and South Indians (ASI) with (DN) and without nephropathy (DM) for the four inflammatory variants.</title><p>&#x0002a;p&#x0003c;0.05 Asian North Indians (ANI) vs. Asian South Indians (ASI). DM: Diabetes without nephropathy; DN: Diabetes with nephropathy.</p></caption><graphic xlink:href="pone.0005168.g003"/></fig><fig id="pone-0005168-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005168.g004</object-id><label>Figure 4</label><caption><title>Univariate logistic regression analysis in type 2 diabetic patients with <italic>TGFB1</italic> 869 (T&#x0003e;C), <italic>CCL2</italic> -2518 (A&#x0003e;G), <italic>CCL2</italic> (Del.&#x0003e;Ins.), <italic>IL8</italic> -251 (T&#x0003e;A), <italic>CCR5</italic> Del 32 (Ins.&#x0003e;Del.), and <italic>MMP9</italic> Arg279Gln (G&#x0003e;A) polymorphisms as independent and diabetic nephropathy as a dependent variable among South Indian Cohort.</title><p>&#x0002a;p&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0005168.g004"/></fig><fig id="pone-0005168-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005168.g005</object-id><label>Figure 5</label><caption><title>Multivariate logistic regression analysis in type 2 diabetic patients with <italic>TGFB1</italic> 869 (T&#x0003e;C), <italic>CCL2</italic> -2518 (A&#x0003e;G), <italic>CCL2</italic> (Del.&#x0003e;Ins.), <italic>IL8</italic> -251 (T&#x0003e;A), <italic>CCR5</italic> Del 32 (Ins.&#x0003e;Del.), and <italic>MMP9</italic> Arg279Gln (G&#x0003e;A) polymorphisms as independent and diabetic nephropathy as a dependent variable among South Indian Cohort.</title><p>&#x0002a;p&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0005168.g005"/></fig><sec id="s2c1"><title>Power calculations</title><p>Power assuming &#x003b1;&#x0200a;&#x0003d;&#x0200a;0.05 and relative risk of 1.4 was 62&#x00025;, 83&#x00025;, 85&#x00025; and 79&#x00025; for type 2 diabetic patients with diabetic nephropathy for <italic>IL8, CCL2, CCR5, MMP9</italic> polymorphisms (p&#x0003c;0.05) among North Indian population.</p></sec></sec><sec id="s2d"><title>Gene&#x02013;gene interaction</title><p>We analyzed the presence of epistatic interactions amongst inflammatory genes, evaluating the possible (one-to-four way) SNP combinations using the multiple dimensionality reduction approach (MDR). All the four models (one, two, three &#x00026; four locus) had a prediction accuracy of &#x0003e;63&#x00025; and showed significant interactions (p&#x0003c;0.05), as determined empirically by permutation testing. Four loci SNP combination of -2518AG (<italic>CCL2</italic>), II/ID (<italic>CCL2</italic> I/D), 279Gln/Arg (<italic>MMP9</italic>), and DD (<italic>CCR5</italic> I/D) genotypes was found to be the best model for DN risk prediction (accuracy 0.764; p&#x0200a;&#x0003d;&#x0200a;0.0001, <xref ref-type="fig" rid="pone-0005168-g006">Figure 6</xref>). The predicted odds ratio of this model was 10.6 (95&#x00025; CI: 6.6&#x02013;17.0). The two loci model comprising II genotype (<italic>CCL2</italic>) and DD genotype (<italic>CCR5</italic>) and three loci combination comprising of II (<italic>CCL2</italic> I/D), DD (<italic>CCR5</italic> I/D), and -2518AG (<italic>CCL2</italic>) were also significantly associated with three and five folds risk of DN (p&#x0200a;&#x0003d;&#x0200a;0.0001; p&#x0003c;0.02).</p><fig id="pone-0005168-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005168.g006</object-id><label>Figure 6</label><caption><title>Gene&#x02013;Gene interaction: Comparison between the number of interacting locus/loci and the odds ratio (relative risk) pertaining to each SNP combination.</title><p>Testing Accuracy for different combinations: single locus, 63.7 &#x00025;; two locus, 65.1&#x00025;; three locus, 70.7&#x00025;; four locus, 76.4&#x00025;.</p></caption><graphic xlink:href="pone.0005168.g006"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>Recent studies suggest inflammation to be an essential component of type 2 DM and its complications. We measured hs-CRP as a marker of inflammation in our diabetic cohort and found its levels to be significantly higher in diabetic patients as compared to controls and in nephropathy group as compared to diabetic subjects without nephropathy indicating inflammation to be a relevant factor in the pathogenesis of DN. Our results are consistent with an earlier study which has also reported increased hs-CRP levels in diabetics with proteinuria <xref ref-type="bibr" rid="pone.0005168-Navarro1">&#x0005b;18&#x0005d;</xref>.</p><p>Different inflammatory molecules, including pro-inflammatory cytokines have been proposed as critical factors in the development of microvascular diabetic complications, including nephropathy <xref ref-type="bibr" rid="pone.0005168-Rivero1">&#x0005b;19&#x0005d;</xref>. It has been suggested that genetic variations in the genes encoding the inflammatory cytokines might confer susceptibility to DN by altering the function and/or expression of these cytokines. We investigated the association of genetic polymorphism(s) in inflammatory genes with the risk of diabetic nephropathy and whether co-occurrence of risk conferring variants of inflammatory genes were associated with increased risk of diabetic nephropathy in Asian Indian type 2 diabetic subjects. The key finding of our study was that polymorphisms in <italic>IL8</italic>, <italic>CCL2</italic>, <italic>CCR5</italic>, and <italic>MMP9</italic> genes were associated with increased risk of nephropathy in Asian Indian type 2 diabetics and co-occurrence of specific risk genotypes of these genes conferred several fold greater risk of diabetic nephropathy.</p><p>We examined eight variants of five pro-inflammatory cytokine genes which have been either shown to be linked with DN in other ethnic populations or were functional variants affecting expression or function of these genes. All the examined genotypes/alleles were in Hardy-Weinberg Equilibrium in both DN and DM groups. We observed that specific genotypes of all the genes except <italic>TGFB1</italic>, showed independent association with risk of DN.</p><p>CCL2, also known as Monocyte chemo-attractant protein-1 (MCP-1), is the strongest known chemo-tactic factor for monocytes and is upregulated in DN. Recent studies suggest that this cytokine is involved in the pathogenesis of diabetic nephropathy <xref ref-type="bibr" rid="pone.0005168-Ibrahim1">&#x0005b;20&#x0005d;</xref>. We examined two polymorphisms, <italic>CCL2</italic> A-2518G and <italic>CCL2</italic> Insertion/Deletion in CCL2 gene for association with DN. <italic>CCL2</italic> -2518AG and <italic>CCL2</italic> II genotypes showed two fold higher risk of DN as compared to DM group. The -2518A allele (<italic>CCL2</italic>) was reported to be associated with kidney failure in Korean type 2 DM patients. This SNP has been shown to influence <italic>CCL2</italic> transcriptional activity, with increased CCL2 protein expression in GG/AG genotype carriers as compared to AA carriers in response to IL1B <xref ref-type="bibr" rid="pone.0005168-Maeda3">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005168-Mlynarski1">&#x0005b;21&#x0005d;</xref>. The <italic>CCL2</italic> I/D polymorphism has been recently reported to be associated with development of inflammatory myopathies <xref ref-type="bibr" rid="pone.0005168-Chinoy1">&#x0005b;22&#x0005d;</xref>. This is the first report of this variant being examined for association with type 2diabetes or nephropathy among Asian Indians.</p><p>A common 32-bp deletion mutation (<italic>CCR5</italic> del 32) and a promoter polymorphism CCR5 59029 (G/A) of the CCR5 gene have recently been reported to be associated with the increased risk of nephropathy in type 1 <xref ref-type="bibr" rid="pone.0005168-Mlynarski1">&#x0005b;21&#x0005d;</xref> and type 2 diabetic subjects <xref ref-type="bibr" rid="pone.0005168-Nakajima1">&#x0005b;15&#x0005d;</xref>. We too observed a significant association of <italic>CCR5</italic> 59029AA variants with increased risk of DN in our North Indian cohort. Our results are in conformity with other available reports of association of this marker with DN among Asian Indians <xref ref-type="bibr" rid="pone.0005168-Prasad1">&#x0005b;6&#x0005d;</xref> and Japanese population <xref ref-type="bibr" rid="pone.0005168-Mokubo1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005168-Nakajima1">&#x0005b;15&#x0005d;</xref> and suggest that the <italic>CCR5</italic> 59029 A allele may be an independent risk factor for diabetic nephropathy in patients with type 2 diabetes. <italic>CCR5</italic> 59029A-genotype has been shown to be associated with increased <italic>CCR5</italic> expression by peripheral blood mononuclear cells has been seen in individuals with the <xref ref-type="bibr" rid="pone.0005168-McDermott1">&#x0005b;23&#x0005d;</xref>, thereby suggesting that the genotype could regulate <italic>CCR5</italic> gene expression. We found <italic>CCR5</italic> D allele to be associated with increased risk of DN in our North Indian cohort. Limited literature exists regarding the role of this polymorphism in diseases other than AIDS. Male carriers of the 32-bp deletion have been found to be at significantly higher risk of diabetic nephropathy than non-carriers in type 1 diabetes <xref ref-type="bibr" rid="pone.0005168-Mlynarski1">&#x0005b;21&#x0005d;</xref>. This deletion alters the open reading frame of the gene resulting in a truncated protein <xref ref-type="bibr" rid="pone.0005168-Gonzalez1">&#x0005b;24&#x0005d;</xref>. Thus, a genetically determined impairment in the function of the chemokine receptor CCR5 may change the profile of recruited cells, and this may promote, for example, renal fibrosis instead of normal tissue repair <xref ref-type="bibr" rid="pone.0005168-Vielhauer1">&#x0005b;25&#x0005d;</xref>.</p><p>We found -251AA genotype (<italic>IL8</italic>) to be associated with higher risk of DN. The <italic>IL8</italic> T-251A variant lies in the regulatory region and increases the gene expression <xref ref-type="bibr" rid="pone.0005168-Hull1">&#x0005b;26&#x0005d;</xref>, suggesting that this genotype could regulate IL8 gene expression. Increased urinary excretion of IL8 has been reported in DN patients <xref ref-type="bibr" rid="pone.0005168-Tashiro1">&#x0005b;27&#x0005d;</xref>. This variant has been associated with inflammatory renal injury <xref ref-type="bibr" rid="pone.0005168-Rovin1">&#x0005b;28&#x0005d;</xref>. Ours is the first study showing an association of this allele with increased risk of diabetic nephropathy.</p><p>The <italic>MMP9</italic> Arg279Gln polymorphism lies in the substrate binding region and decreases binding affinity of type IV collagen to <italic>MMP9</italic><xref ref-type="bibr" rid="pone.0005168-Shipley1">&#x0005b;29&#x0005d;</xref>. <italic>MMP9</italic> 279Gln/Gln genotypes was found to be associated with increased risk of DN suggesting that decreased affinity of type IV collagen to MMP9 may lead to decreased degradation leading to over-accumulation of such extracellular matrix (ECM) proteins and contributing to renal damage <xref ref-type="bibr" rid="pone.0005168-Falk1">&#x0005b;30&#x0005d;</xref>. However, further studies are required to confirm the functional impact of this variant on diabetic nephropathy.</p><p><italic>TGFB1</italic> Tyr81His polymorphism is a functional SNP in the Exon 2 of <italic>TGFB1</italic> gene and has been previously studied in Asian Indians with chronic renal insufficiency (6). This SNP was found to be monomorphic in our population and was further not analysed. The minor allele frequency (MAF) of the second <italic>TGFB1</italic> SNP T869C (Leu10Pro) was similar in cases and controls (p&#x0003e;0.05). Similar results have been reported in Japanese <xref ref-type="bibr" rid="pone.0005168-Akai1">&#x0005b;31&#x0005d;</xref> and Caucasians <xref ref-type="bibr" rid="pone.0005168-Pociot1">&#x0005b;32&#x0005d;</xref> where, no association between this SNP and DN was observed. However, Wong et al. <xref ref-type="bibr" rid="pone.0005168-Wong2">&#x0005b;33&#x0005d;</xref> found 869CC genotype to be associated with DN in Chinese diabetic subjects. The observed heterogeneity in these results could be due to ethnic differences in these studies.</p><p>None of the polymorphisms in our study showed any association with hs-CRP levels. A lack of association between IL6 G-174C or IL1 RA genotypes and significant association between CRP and diabetic nephropathy has been reported earlier too, indicating that elevated CRP levels are associated with diabetic nephropathy independent of polymorphisms in cytokine genes <xref ref-type="bibr" rid="pone.0005168-Lee1">&#x0005b;34&#x0005d;</xref>.</p><p>We replicated genotypic associations seen in our cohort in an independently recruited set of diabetic patients from Southern India. We observed that the MAF of the four of risk conferring SNPs (<italic>CCL2</italic> ID, <italic>CCR5</italic> G59029A, <italic>MMP9</italic> Arg279Gln, and <italic>IL8</italic> T-251A) were similar in North and South Indian populations and were associated with increased risk of DN. However, the &#x02018;D&#x02019; allele frequency (<italic>CCR5</italic> I/D polymorphism) was higher in North Indian DN group as compared to the South Indian DN group, and did not show association with the risk of nephropathy in the latter. These differences may be because of the ethnic variation between the North and South Indian populations <xref ref-type="bibr" rid="pone.0005168-Basu1">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005168-Singh1">&#x0005b;36&#x0005d;</xref> and/or comparatively small sample size of South Indian subjects in our cohort. However, the replication of our data in two independent sets of populations suggests that these associations might be significant.</p><p>We analyzed the interaction of the individual genotypes for conferring nephropathy risk using multifactor dimensionality reduction (MDR) software. MDR method was developed by Hahn et al <xref ref-type="bibr" rid="pone.0005168-Hahn1">&#x0005b;37&#x0005d;</xref> for collapsing high-dimensional genetic data into a single dimension thus permitting interactions to be detected in relatively small sample sizes. It identifies combinations of multilocus genotypes and discrete environmental factors (non-linear interactions) that are associated with a particular disease. It calculates the testing accuracy/Prediction error after taking into account the number of samples. It has been used in several other similar studies <xref ref-type="bibr" rid="pone.0005168-Ritchie1">&#x0005b;38&#x0005d;</xref>. We observed significant epistatic interactions between <italic>CCL2</italic>, <italic>CCR5</italic> and <italic>MMP9</italic> gene SNPs. A four loci combination of genotypes: &#x0005b;-2518AG (<italic>CCL2</italic>)&#x0002b;II/ID (<italic>CCL2</italic> I/D)&#x0002b;279Arg/Gln (<italic>MMP9</italic>)&#x0002b;DD (<italic>CCR5</italic> I/D)&#x0005d; was associated with ten fold increased risk of DN as compared to the risk conferred by individual genotypes, suggesting a synergistic interaction between these genes towards disease susceptibility.</p><p>A relatively small sample size such as ours may be a limitation for genetic studies; however, few investigators (mostly multi-centric) have access to larger sample sizes. The strength of our study is that we had an ethnically homogenous and well phenotyped diabetic subjects enrolled from a single centre, thereby reducing phenotyping errors and bias. The inclusion criterion of absence of microalbuminuria on two or more occasions for the control group ensured a good selection of control diabetic group for the study. Also, in accordance with the suggestions of Hattersley and McCarthy <xref ref-type="bibr" rid="pone.0005168-Hattersley1">&#x0005b;39&#x0005d;</xref>, the present study fulfils most of the prerequisites for a good genetic association study. Further, most of the variants showing positive association had a minimum power of 76&#x00025;, which has been shown to be adequate for association studies <xref ref-type="bibr" rid="pone.0005168-Neale1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005168-Wacholder1">&#x0005b;41&#x0005d;</xref>.</p><p>In summary, our study provides evidence of the individual risk associated with the inflammatory gene variants and also emphasizes on the combinatorial effect of alleles of the <italic>CCL2</italic> (I allele of I/D polymorphism), <italic>CCR5</italic> (D allele of I/D polymorphism) and <italic>MMP9</italic> (279Gln allele of Arg279Gln) genes for diabetic nephropathy, considering the epistatic effects of individual genes, while investigating susceptibility genes in complex diseases like DN among Asian Indians.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Subject Selection</title><p>Two independently recruited groups of Type 2 diabetes (T2DM) patients and control subjects were evaluated. The first group consisted of unrelated 255 individuals with T2DM and no nephropathy (DM) and 240 consecutive diabetic nephropathy patients (DN), from North India, attending outpatient diabetes and nephrology clinics at Post Graduate Institute of Medical Education and research (PGIMER), Chandigarh, India. Replication studies were performed on a population of 92 cases with T2DM without nephropathy and 96 DN patients recruited from Madras Diabetes Research foundation (MDRF), Chennai, South India enrolled in Chennai Urban Rural Epidemiology Study (CURES) <xref ref-type="bibr" rid="pone.0005168-Pociot1">&#x0005b;32&#x0005d;</xref>. An informed written consent was taken from all the subjects participating in this study.</p><p>Type 2 diabetes was diagnosed on the basis of the WHO criteria. The patients were divided into subgroups: type 2 diabetes patients who had the disease for at least 10 years but remained free of nephropathy (DM) and patients with nephropathy (DN). Diabetic nephropathy status was determined on the basis of a questionnaire, clinical features and laboratory data. Type 2 diabetic subjects diagnosed with either of the following: a) Urinary albumin &#x0003e;300 mg/L or, b) an albumin:creatinine ratio &#x0003e;300 &#x000b5;g/mg without any clinical or laboratory evidence of other kidney disease, formed the diabetic nephropathy group. Type 2 diabetes subjects with duration of onset of 10 years or more and negative for urinary protein (proteinuria) and urinary albumin levels &#x0003c;30 mg/L (measured on two consecutive occasions) formed DM group. It was ensured that the diabetic nephropathy subjects had no microscopic hematuria. In addition, the diabetic subjects (without proteinuria) on anti-hypertensive drug treatment were excluded from the study group in order to avoid misclassification of phenotype. All the subjects in both groups were age, &#x00026; ethnicity matched. The research carried out was in compliance with the Helsinki Declaration.</p></sec><sec id="s4b"><title>Ethics Statement</title><p>The study was approved by the Ethics committee of Post Graduate Institute of Medical Education and Research, Chandigarh, India and also by the Ethics committee of Madras Diabetes Research Foundation, Chennai, India.</p></sec><sec id="s4c"><title>SNP Selection and Genotyping Analysis</title><p>The genomic DNA was isolated from peripheral blood, using the Proteinase K-chloroform-phenol method. A total of 8 SNPs of five candidate genes (<italic>TGFB1, CCL2, CCR5, IL8,</italic> and <italic>MMP9</italic>) were selected for the present study, SNPs were chosen based either on their location or functional nature (promoter or exonic) or on their widely analyzed status. Details including location of SNPs in their respective genes, primer sequences, PCR conditions and restriction enzyme with product sizes are given in <xref ref-type="table" rid="pone-0005168-t003">Table 3</xref>. The digested PCR products were run on 12&#x00025; polyacrylamide gel followed by silver staining.</p><table-wrap id="pone-0005168-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005168.t003</object-id><label>Table 3</label><caption><title>Standard PCR conditions used in genotyping the inflammatory gene variants.</title></caption><graphic id="pone-0005168-t003-3" xlink:href="pone.0005168.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005168-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP (rs#) <italic>Gene</italic></td><td align="left" rowspan="1" colspan="1">Primers</td><td align="left" rowspan="1" colspan="1">Amplicon (bp)</td><td align="left" rowspan="1" colspan="1">Annealing temp. (&#x000b0;C)/&#x0005b;MgCl<sub>2</sub>&#x0005d; (mmol)</td><td align="left" rowspan="1" colspan="1">Restriction Enz./Allele size</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>869T&#x0003e;C (Leu10Pro) (rs1800470)</bold></td><td align="left" rowspan="1" colspan="1">P1: <named-content content-type="gene">5&#x02032;-TTC AAG ACC ACC CAC CTT CT-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1">443</td><td align="left" rowspan="1" colspan="1">68.2/1.5</td><td align="left" rowspan="1" colspan="1">Msp A1I (NEB)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>TGFB1</italic></bold></td><td align="left" rowspan="1" colspan="1">P2: <named-content content-type="gene">5&#x02032;-TCG CGG GTG CTG TTG TAC A-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;285, 67, 50, 41 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Exon 1</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C&#x0200a;&#x0003d;&#x0200a;273, 67, 50, 41, 12 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Tyr81His (T&#x0003e;C)</bold></td><td align="left" rowspan="1" colspan="1">P1: <named-content content-type="gene">5&#x02032;-CCA GAT CCT GTC CAA GCT G-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1">198</td><td align="left" rowspan="1" colspan="1">57.9/2.5</td><td align="left" rowspan="1" colspan="1">Rsa I (NEB)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>TGFB1</italic></bold></td><td align="left" rowspan="1" colspan="1">P2: <named-content content-type="gene">5&#x02032;-TGG GTT TCC ACC ATT AGC AC-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;109, 89 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Exon 2</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C&#x0200a;&#x0003d;&#x0200a;198 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>-2518 A&#x0003e;G</bold></td><td align="left" rowspan="1" colspan="1">P1: <named-content content-type="gene">5&#x02032;-TCT CTC ACG CCA GCA CTG ACC-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1">234</td><td align="left" rowspan="1" colspan="1">59.4/3.0</td><td align="left" rowspan="1" colspan="1">Pvu II (NEB)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>(rs1024611)</bold></td><td align="left" rowspan="1" colspan="1">P2: <named-content content-type="gene">5&#x02032;-GAG TGT TCA CAT AGG CTT CTG-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;159, 75 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCL2</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;234 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Promoter</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ins./Del.</bold></td><td align="left" rowspan="1" colspan="1">P1: <named-content content-type="gene">5&#x02032;-GCT GAT CTT CCC TGG TGC TGA T-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1">202/188</td><td align="left" rowspan="1" colspan="1">61.3/3.0</td><td align="left" rowspan="1" colspan="1">I&#x0200a;&#x0003d;&#x0200a;202 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>(rs3917887)</bold></td><td align="left" rowspan="1" colspan="1">P2: <named-content content-type="gene">5&#x02032;- CAT TAA ATC CCA GTG CTT CTG CCT</named-content> A -3&#x02032;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D&#x0200a;&#x0003d;&#x0200a;188 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCL2</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Intron 1</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Del 32</bold></td><td align="left" rowspan="1" colspan="1">P1: <named-content content-type="gene">5&#x02032;-GAA GTT CCT CAT TAC ACC TGC AGC TCT C-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1">174/142</td><td align="left" rowspan="1" colspan="1">63.5/3.5</td><td align="left" rowspan="1" colspan="1">I&#x0200a;&#x0003d;&#x0200a;174 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCR5</italic></bold></td><td align="left" rowspan="1" colspan="1">P2: <named-content content-type="gene">5&#x02032;- CTT CTT CTC ATT TCG ACA CCG AAG CAG AG-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D&#x0200a;&#x0003d;&#x0200a;142 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Promoter</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>59029 G&#x0003e;A</bold></td><td align="left" rowspan="1" colspan="1">P1: <named-content content-type="gene">5&#x02032;-CAG TCA ACC TGG GCA AAG CC-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1">453</td><td align="left" rowspan="1" colspan="1">56.5/2.5</td><td align="left" rowspan="1" colspan="1">Bst 1286I (NEB)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>CCR5</italic></bold></td><td align="left" rowspan="1" colspan="1">P2: <named-content content-type="gene">5&#x02032;-AGC TTT GGT CCT GAG AGT CC-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">G&#x0200a;&#x0003d;&#x0200a;408, 45 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;453 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Promoter</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>-251 T&#x0003e;A</bold></td><td align="left" rowspan="1" colspan="1">P1: <named-content content-type="gene">5&#x02032;(1A)-CTA GAA ATA AAA AAG CAT ACA A -3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1">240/250</td><td align="left" rowspan="1" colspan="1">53.8/3.0</td><td align="left" rowspan="1" colspan="1">A&#x0200a;&#x0003d;&#x0200a;240 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>(rs4073)</bold></td><td align="left" rowspan="1" colspan="1">P2: <named-content content-type="gene">5&#x02032;(2T)-ATA AAG TTA TCT AGA AAT AAA AAA GCA TAT AT-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">T&#x0200a;&#x0003d;&#x0200a;250 bp</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>IL8</italic></bold></td><td align="left" rowspan="1" colspan="1">P3: <named-content content-type="gene">5&#x02032;-TAG AGA ACT TAT GCA CCC TCA-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Promoter</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Arg279Gln G&#x0003e;A</bold></td><td align="left" rowspan="1" colspan="1">P1: <named-content content-type="gene">CTCCTCGCCCCAGGACTCT</named-content></td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">TaqMan assay</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>(rs17576)</bold></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ACACCC&#x0005b;A/G&#x0005d;GGACGGCAATGC</named-content></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>MMP9</italic></bold></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGATGGGAAACCC</named-content></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Exon 6</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt108"><label>&#x0002a;</label><p>The primers for these SNPs have been designed using Primer 3 software.</p></fn></table-wrap-foot></table-wrap><p>One SNP, <italic>MMP9</italic> Gly279Arg was genotyped using the TaqMan allelic discrimination Assay, using the Applied Biosystems 7300 Real-Time PCR System, USA. Two reporter dyes VIC and FAM were used to label the Allele 1 and 2 probes and a 5&#x02032; Nuclease Assay was carried out. Fluorescence was then measured followed by automatic allele calling.</p></sec><sec id="s4d"><title>Biochemical Investigations</title><p>Serum creatinine, blood urea, triglycerides, HDL, total cholesterol, and blood glucose levels were measured using their respective kits; high sensitive C Reactive Protein (hs-CRP) was assayed using Enzyme Linked Immuno-Sorbent Assay (ELISA) (Calbiotech Inc., USA) as per instructions of the manufacturer.</p></sec><sec id="s4e"><title>Statistical analysis</title><p>The statistical tests were performed, using the Statistical package for Social Sciences (SPSS Inc., Chicago, IL, USA) version 13.0. Discrete and continuous variables were compared between various groups using Pearson's &#x003c7;<sup>2</sup> test and unpaired t-test as appropriate. Parameters showing skewed distribution (diastolic and systolic blood pressure, and serum creatinine) were compared using Mann-Whitney U test. Pearson's &#x003c7;<sup>2</sup> test (3&#x000d7;2 contingency table) was used to assess association of SNPs with renal disease between the diabetic nephropathy group (cases) and diabetes without nephropathy group (controls). Significant allelic and genotypic associations calculated by Pearson's &#x003c7;<sup>2</sup> test were used for evaluating odds ratio (O.R.) and 95&#x00025; confidence intervals (CI) as well. The genotypes at their respective loci were coded as recessive (e.g., <italic>TGFB1</italic> 869TT vs. 869TC&#x0002b;CC) and as dominant models (e.g., <italic>TGFB1</italic> 869CC vs. TC&#x0002b;TT). The seven polymorphisms were then assessed for relation by univariate logistic regression analysis and further the variables showing a statistically significant association were made to undergo multivariate regression analysis. Power of the sample size (subjects) was calculated using the Power for Association with Errors (PAWE) software (<ext-link ext-link-type="uri" xlink:href="http://linkage.rockefeller.edu/pawe">http://linkage.rockefeller.edu/pawe</ext-link>) <xref ref-type="bibr" rid="pone.0005168-Gordon1">&#x0005b;42&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005168-Gordon2">&#x0005b;43&#x0005d;</xref>. Hardy Weinberg Equilibrium was calculated as performed previously <xref ref-type="bibr" rid="pone.0005168-Nielsen1">&#x0005b;44&#x0005d;</xref>. We evaluated the gene&#x02013;gene interactions (intra and inter) among the large number of loci in our study using the multiple dimensionality reduction (MDR) method (<ext-link ext-link-type="uri" xlink:href="http://www.epistasis.org/open-source-mdrproject.html">http://www.epistasis.org/open-source-mdrproject.html</ext-link>).</p></sec></sec></body><back><ack><p>The study was carried out at Hypertension Genomics Laboratory, PGIMER, Chandigarh, India. We are grateful to the volunteers of this study, the laboratory staff, and all who contributed in terms of time and effort.</p></ack><ref-list><title>References</title><ref id="pone.0005168-Greene1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname><given-names>CN</given-names></name><name><surname>Keong</surname><given-names>LM</given-names></name><name><surname>Cordovado</surname><given-names>SK</given-names></name><name><surname>Mueller</surname><given-names>PW</given-names></name></person-group><year>2008</year><article-title>Sequence variants in the PLEKHH2 region are associated with diabetic nephropathy in the GoKinD study population.</article-title><source>Hum Genet</source><volume>3</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">18752002</pub-id></citation></ref><ref id="pone.0005168-Ahluwalia1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahluwalia</surname><given-names>TS</given-names></name><name><surname>Ahuja</surname><given-names>M</given-names></name><name><surname>Rai</surname><given-names>TS</given-names></name><name><surname>Kohli</surname><given-names>HS</given-names></name><name><surname>Sud</surname><given-names>K</given-names></name><etal/></person-group><year>2008</year><article-title>Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians.</article-title><source>Mol Cell Biochem</source><volume>314</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">18401556</pub-id></citation></ref><ref id="pone.0005168-Hanson1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>RL</given-names></name><name><surname>Craig</surname><given-names>DW</given-names></name><name><surname>Millis</surname><given-names>MP</given-names></name><name><surname>Yeatts</surname><given-names>KA</given-names></name><name><surname>Kobes</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Identification of PVT1 as a Candidate Gene for End-Stage Renal Disease in Type 2 Diabetes Using a Pooling-Based Genome-Wide Single Nucleotide Polymorphism Association Study.</article-title><source>Diabetes</source><volume>56</volume><fpage>975</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">17395743</pub-id></citation></ref><ref id="pone.0005168-Maeda1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Osawa</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Tsukada</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population.</article-title><source>Kidney Int</source><volume>106</volume><fpage>S43</fpage><lpage>S48</lpage></citation></ref><ref id="pone.0005168-Hirakawa1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirakawa</surname><given-names>S</given-names></name><name><surname>Lange</surname><given-names>EM</given-names></name><name><surname>Colicigno</surname><given-names>CJ</given-names></name><name><surname>Freedman</surname><given-names>BI</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><etal/></person-group><year>2003</year><article-title>Evaluation of genetic variation and association in the matrix metalloproteinase 9 (MMP9) gene in ESRD patients.</article-title><source>Am J Kidney Dis</source><volume>42</volume><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">12830465</pub-id></citation></ref><ref id="pone.0005168-Prasad1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>P</given-names></name><name><surname>Tiwari</surname><given-names>AK</given-names></name><name><surname>Kumar</surname><given-names>KMP</given-names></name><name><surname>Ammini</surname><given-names>AC</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><etal/></person-group><year>2007</year><article-title>Association of TGFB1, TNF&#x003b1;, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians.</article-title><source>BMC Medical Genetics</source><volume>8</volume><fpage>20</fpage><pub-id pub-id-type="pmid">17428349</pub-id></citation></ref><ref id="pone.0005168-Prasad2"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>P</given-names></name><name><surname>Tiwari</surname><given-names>AK</given-names></name><name><surname>Kumar</surname><given-names>KMP</given-names></name><name><surname>Ammini</surname><given-names>AC</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms.</article-title><source>BMC Medical Genetics</source><volume>7</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">16672053</pub-id></citation></ref><ref id="pone.0005168-Ruster1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruster</surname><given-names>C</given-names></name><name><surname>Wolf</surname><given-names>G</given-names></name></person-group><year>2008</year><article-title>The role of chemokines and chemokine receptors in diabetic nephropathy.</article-title><source>Front Biosci</source><volume>13</volume><fpage>944</fpage><lpage>955</lpage><pub-id pub-id-type="pmid">17981602</pub-id></citation></ref><ref id="pone.0005168-NavarroGonzalez1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navarro-Gonzalez</surname><given-names>JF</given-names></name><name><surname>Mora-Fernandez</surname><given-names>C</given-names></name></person-group><year>2008</year><article-title>The role of inflammatory cytokines in diabetic nephropathy.</article-title><source>J Am Soc Nephrol</source><volume>19</volume><fpage>433</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">18256353</pub-id></citation></ref><ref id="pone.0005168-Maeda2"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>S</given-names></name></person-group><year>2008</year><article-title>Do inflammatory cytokine genes confer susceptibility to diabetic nephropathy?</article-title><source>Kidney Int</source><volume>74</volume><fpage>413</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">18670406</pub-id></citation></ref><ref id="pone.0005168-Moon1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>JY</given-names></name><name><surname>Jeong</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Jeong</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>Association of polymorphisms in monocyte chemoattractant protein-1 promoter with diabetic kidney failure in Korean patients with type 2 diabetes mellitus.</article-title><source>J Korean Med Sci</source><volume>22</volume><fpage>810</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">17982227</pub-id></citation></ref><ref id="pone.0005168-Wong1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Poon</surname><given-names>P</given-names></name><name><surname>Chow</surname><given-names>KM</given-names></name><name><surname>Szeto</surname><given-names>CC</given-names></name><name><surname>Cheung</surname><given-names>MK</given-names></name><etal/></person-group><year>2003</year><article-title>Association of transforming growth factor-beta (TGF-beta) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese.</article-title><source>Kidney Int</source><volume>63</volume><fpage>1831</fpage><lpage>1835</lpage><pub-id pub-id-type="pmid">12675860</pub-id></citation></ref><ref id="pone.0005168-Maeda3"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Haneda</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>B</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><etal/></person-group><year>2001</year><article-title>Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with type 2 diabetic nephropathy.</article-title><source>Kidney Int</source><volume>60</volume><fpage>1428</fpage><lpage>1434</lpage><pub-id pub-id-type="pmid">11576356</pub-id></citation></ref><ref id="pone.0005168-Mokubo1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mokubo</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Watada</surname><given-names>H</given-names></name><name><surname>Hirose</surname><given-names>T</given-names></name><etal/></person-group><year>2006</year><article-title>Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism (59029A/G) is associated with diabetic nephropathy in Japanese patients with type 2 diabetes: A 10-year longitudinal study.</article-title><source>Diabetes Research and Clinical Practice</source><volume>73</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16442182</pub-id></citation></ref><ref id="pone.0005168-Nakajima1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Nomiyama</surname><given-names>T</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name><name><surname>Piao</surname><given-names>L</given-names></name><etal/></person-group><year>2002</year><article-title>Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes.</article-title><source>Diabetes</source><volume>51</volume><fpage>238</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">11756347</pub-id></citation></ref><ref id="pone.0005168-Ahluwalia2"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahluwalia</surname><given-names>TS</given-names></name><name><surname>Ahuja</surname><given-names>M</given-names></name><name><surname>Rai</surname><given-names>TS</given-names></name><name><surname>Kohli</surname><given-names>HS</given-names></name><name><surname>Bhansali</surname><given-names>A</given-names></name><etal/></person-group><year>2009</year><article-title>ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy.</article-title><source>DNA Cell Biology</source><volume>28</volume><fpage>141</fpage><lpage>150</lpage></citation></ref><ref id="pone.0005168-Jacobsen1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>P</given-names></name><name><surname>Tarnow</surname><given-names>L</given-names></name><name><surname>Carstensen</surname><given-names>B</given-names></name><name><surname>Hovind</surname><given-names>P</given-names></name><name><surname>Poirier</surname><given-names>O</given-names></name><etal/></person-group><year>2003</year><article-title>Genetic variation in the renin&#x02013;angiotensin system and progression of diabetic nephropathy.</article-title><source>J Am Soc Nephrol</source><volume>14</volume><fpage>2843</fpage><lpage>2850</lpage><pub-id pub-id-type="pmid">14569094</pub-id></citation></ref><ref id="pone.0005168-Navarro1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>JF</given-names></name><name><surname>Mora</surname><given-names>C</given-names></name><name><surname>Muros</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>J</given-names></name></person-group><year>2006</year><article-title>Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients.</article-title><source>Nephrol Dial Transplant</source><volume>21</volume><fpage>3428</fpage><lpage>3434</lpage><pub-id pub-id-type="pmid">16935891</pub-id></citation></ref><ref id="pone.0005168-Rivero1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rivero</surname><given-names>A</given-names></name><name><surname>Mora</surname><given-names>C</given-names></name><name><surname>Muros</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>J</given-names></name><name><surname>Herrera</surname><given-names>H</given-names></name><name><surname>Navarro-Gonz&#x000e1;lez</surname><given-names>JF</given-names></name></person-group><year>2009</year><article-title>Pathogenic perspectives for the role of inflammation in diabetic nephropathy.</article-title><source>Clin Sci (Lond)</source><volume>116</volume><fpage>479</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">19200057</pub-id></citation></ref><ref id="pone.0005168-Ibrahim1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>S</given-names></name><name><surname>Rashed</surname><given-names>L</given-names></name></person-group><year>2008</year><article-title>Correlation of urinary monocyte chemo-attractant protein-1 with other parameters of renal injury in type-II diabetes mellitus.</article-title><source>Saudi J Kidney Dis Transpl</source><volume>19</volume><fpage>911</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">18974575</pub-id></citation></ref><ref id="pone.0005168-Mlynarski1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mlynarski</surname><given-names>WM</given-names></name><name><surname>Placha</surname><given-names>GP</given-names></name><name><surname>Wolkow</surname><given-names>PP</given-names></name><name><surname>Bochenski</surname><given-names>JP</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name><etal/></person-group><year>2005</year><article-title>Risk of Diabetic Nephropathy in Type 1 Diabetes Is Associated With Functional Polymorphisms in RANTES Receptor Gene (CCR5).</article-title><source>Diabetes</source><volume>54</volume><fpage>3331</fpage><lpage>3335</lpage><pub-id pub-id-type="pmid">16249462</pub-id></citation></ref><ref id="pone.0005168-Chinoy1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chinoy</surname><given-names>H</given-names></name><name><surname>Salway</surname><given-names>F</given-names></name><name><surname>Fertig</surname><given-names>N</given-names></name><name><surname>Tait</surname><given-names>BD</given-names></name><name><surname>Oddis</surname><given-names>CV</given-names></name><name><surname>Ollier</surname><given-names>WER</given-names></name><name><surname>Cooper</surname><given-names>RG</given-names></name></person-group><year>2006</year><article-title>Monocyte chemotactic protein-1 single nucleotide polymorphisms do not confer susceptibility for the development of adult onset polymyositis/dermatomyositis in UK Caucasians.</article-title><source>Rheumatology</source><comment>1-4, doi:10.1093/rheumatology/kel359</comment></citation></ref><ref id="pone.0005168-McDermott1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDermott</surname><given-names>DH</given-names></name><name><surname>Zimmerman</surname><given-names>PA</given-names></name><name><surname>Guignard</surname><given-names>F</given-names></name><name><surname>Kleeberger</surname><given-names>CA</given-names></name><name><surname>Leitman</surname><given-names>SF</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><year>1998</year><article-title>CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS).</article-title><source>Lancet</source><volume>352</volume><fpage>866</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">9742978</pub-id></citation></ref><ref id="pone.0005168-Gonzalez1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>E</given-names></name><name><surname>Dhanda</surname><given-names>R</given-names></name><name><surname>Bamshad</surname><given-names>M</given-names></name><name><surname>Mummidi</surname><given-names>S</given-names></name><name><surname>Geevarghese</surname><given-names>R</given-names></name><etal/></person-group><year>2001</year><article-title>Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.</article-title><source>Proc Natl Acad Sci USA</source><volume>98</volume><fpage>5199</fpage><lpage>5204</lpage><pub-id pub-id-type="pmid">11320252</pub-id></citation></ref><ref id="pone.0005168-Vielhauer1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vielhauer</surname><given-names>V</given-names></name><name><surname>Anders</surname><given-names>HJ</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Cihak</surname><given-names>J</given-names></name><name><surname>Strutz</surname><given-names>F</given-names></name><etal/></person-group><year>2001</year><article-title>Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes.</article-title><source>J Am Soc Nephrol</source><volume>12</volume><fpage>1173</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">11373340</pub-id></citation></ref><ref id="pone.0005168-Hull1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hull</surname><given-names>J</given-names></name><name><surname>Thomson</surname><given-names>A</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name></person-group><year>2000</year><article-title>Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families.</article-title><source>Thorax</source><volume>55</volume><fpage>1023</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">11083887</pub-id></citation></ref><ref id="pone.0005168-Tashiro1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tashiro</surname><given-names>K</given-names></name><name><surname>Koyanagi</surname><given-names>I</given-names></name><name><surname>Saitoh</surname><given-names>A</given-names></name><name><surname>Shimizu</surname><given-names>A</given-names></name><name><surname>Shike</surname><given-names>T</given-names></name><name><surname>Ishiguro</surname><given-names>C</given-names></name><name><surname>Koizumi</surname><given-names>M</given-names></name><name><surname>Funabiki</surname><given-names>K</given-names></name><name><surname>Horikoshi</surname><given-names>S</given-names></name><name><surname>Shirato</surname><given-names>I</given-names></name><name><surname>Tomino</surname><given-names>Y</given-names></name></person-group><year>2002</year><article-title>Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy.</article-title><source>J Clin Lab Anal</source><volume>16</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11835523</pub-id></citation></ref><ref id="pone.0005168-Rovin1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rovin</surname><given-names>BH</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><year>2002</year><article-title>A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis.</article-title><source>Kidney Int</source><volume>62</volume><fpage>261</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">12081586</pub-id></citation></ref><ref id="pone.0005168-Shipley1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shipley</surname><given-names>JM</given-names></name><name><surname>Doyle</surname><given-names>GA</given-names></name><name><surname>Fliszar</surname><given-names>CJ</given-names></name><name><surname>Ye</surname><given-names>QZ</given-names></name><name><surname>Johnson</surname><given-names>LL</given-names></name><etal/></person-group><year>1996</year><article-title>The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats.</article-title><source>J Biol Chem</source><volume>271</volume><fpage>4335</fpage><lpage>4341</lpage><pub-id pub-id-type="pmid">8626782</pub-id></citation></ref><ref id="pone.0005168-Falk1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falk</surname><given-names>RJ</given-names></name><name><surname>Scheinman</surname><given-names>JI</given-names></name><name><surname>Mauer</surname><given-names>M</given-names></name><name><surname>Michael</surname><given-names>AF</given-names></name></person-group><year>1983</year><article-title>Polyantigenic expansion of basement membrane constituents in diabetic nephropathy.</article-title><source>Diabetes</source><volume>32</volume><issue>Suppl 2</issue><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">6400667</pub-id></citation></ref><ref id="pone.0005168-Akai1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akai</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Ozaki</surname><given-names>H</given-names></name><name><surname>Iwano</surname><given-names>M</given-names></name><name><surname>Dohi</surname><given-names>Y</given-names></name><name><surname>Kanauchi</surname><given-names>M</given-names></name></person-group><year>2001</year><article-title>Association of transforming growth factor-beta1 T29C polymorphism with the progression of diabetic nephropathy.</article-title><source>Am J Kidney Dis</source><volume>38</volume><issue>4 Suppl 1</issue><fpage>S182</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">11576951</pub-id></citation></ref><ref id="pone.0005168-Pociot1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pociot</surname><given-names>F</given-names></name><name><surname>Hansen</surname><given-names>PM</given-names></name><name><surname>Karlsen</surname><given-names>AE</given-names></name><name><surname>Langdahl</surname><given-names>BL</given-names></name><name><surname>Johannesen</surname><given-names>J</given-names></name><name><surname>Nerup</surname><given-names>J</given-names></name></person-group><year>1998</year><article-title>TGF-beta1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy.</article-title><source>J Am Soc Nephrol</source><volume>9</volume><fpage>2302</fpage><lpage>2307</lpage><pub-id pub-id-type="pmid">9848784</pub-id></citation></ref><ref id="pone.0005168-Wong2"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>TYW</given-names></name><name><surname>Poon</surname><given-names>P</given-names></name><name><surname>Chow</surname><given-names>KM</given-names></name><name><surname>Szeto</surname><given-names>CC</given-names></name><name><surname>Cheung</surname><given-names>MK</given-names></name><name><surname>Li</surname><given-names>PKT</given-names></name></person-group><year>2003</year><article-title>Association of transforming growth factor-beta (TGF-&#x003b2;)T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese.</article-title><source>Kidney Int</source><volume>63</volume><fpage>1831</fpage><lpage>1835</lpage><pub-id pub-id-type="pmid">12675860</pub-id></citation></ref><ref id="pone.0005168-Lee1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>TW</given-names></name><name><surname>Ihm</surname><given-names>CG</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Woo</surname><given-names>JT</given-names></name><name><surname>Chung</surname><given-names>JH</given-names></name></person-group><year>2005</year><article-title>Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation.</article-title><source>Nephrology (Carlton)</source><volume>10</volume><issue>Suppl</issue><fpage>S32</fpage><lpage>S36</lpage><pub-id pub-id-type="pmid">16174285</pub-id></citation></ref><ref id="pone.0005168-Basu1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Mukherjee</surname><given-names>N</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>Ethnic India: A Genomic View, With Special Reference to Peopling and Structure.</article-title><source>Genome Res</source><volume>13</volume><fpage>2277</fpage><lpage>2290</lpage><pub-id pub-id-type="pmid">14525929</pub-id></citation></ref><ref id="pone.0005168-Singh1"><label>36</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name></person-group><year>2002</year><source>People of India: Introduction National Series Anthropological Survey of India</source><publisher-loc>Delhi</publisher-loc><publisher-name>Oxford University Press</publisher-name></citation></ref><ref id="pone.0005168-Hahn1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>LW</given-names></name><name><surname>Ritchie</surname><given-names>MD</given-names></name><name><surname>Moore</surname><given-names>JH</given-names></name></person-group><year>2003</year><article-title>Multifactor dimensionality reduction software for detecting gene&#x02013;gene and gene-environment interactions.</article-title><source>Bioinformatics</source><volume>19</volume><fpage>376</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">12584123</pub-id></citation></ref><ref id="pone.0005168-Ritchie1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>MD</given-names></name><name><surname>Hahn</surname><given-names>LW</given-names></name><name><surname>Roodi</surname><given-names>N</given-names></name><name><surname>Bailey</surname><given-names>LR</given-names></name><name><surname>Dupont</surname><given-names>WD</given-names></name><name><surname>Parl</surname><given-names>FF</given-names></name><name><surname>Moore</surname><given-names>JH</given-names></name></person-group><year>2001</year><article-title>Multifactor-Dimensionality Reduction Reveals High-Order Interactions among Estrogen-Metabolism Genes in Sporadic Breast Cancer.</article-title><source>Am J Hum Genet</source><volume>69</volume><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">11404819</pub-id></citation></ref><ref id="pone.0005168-Hattersley1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name></person-group><year>2005</year><article-title>What makes a good genetic association study?</article-title><source>Lancet</source><volume>366</volume><fpage>1315</fpage><lpage>1323</lpage><pub-id pub-id-type="pmid">16214603</pub-id></citation></ref><ref id="pone.0005168-Neale1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Sham</surname><given-names>PC</given-names></name></person-group><year>2004</year><article-title>The future of association studies: gene based analysis and replication.</article-title><source>Am J Hum Genet</source><volume>75</volume><fpage>353</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">15272419</pub-id></citation></ref><ref id="pone.0005168-Wacholder1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Garcia-Closas</surname><given-names>M</given-names></name><name><surname>El Ghormli</surname><given-names>L</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name></person-group><year>2004</year><article-title>Assessing the probability that a positive report is false: an approach for molecular epidemiology studies.</article-title><source>J Natl Cancer Inst</source><volume>96</volume><fpage>434</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">15026468</pub-id></citation></ref><ref id="pone.0005168-Gordon1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Levenstien</surname><given-names>MA</given-names></name><name><surname>Finch</surname><given-names>SJ</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name></person-group><year>2003</year><article-title>Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies.</article-title><source>Pacific Symposium on Biocomputing</source><fpage>490</fpage><lpage>501</lpage><comment>(<ext-link ext-link-type="uri" xlink:href="http://psb.stanford.edu/psb-online/proceedings/psb03/">http://psb.stanford.edu/psb-online/proceedings/psb03/</ext-link>)</comment><pub-id pub-id-type="pmid">12603052</pub-id></citation></ref><ref id="pone.0005168-Gordon2"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Finch</surname><given-names>SJ</given-names></name><name><surname>Nothnagel</surname><given-names>M</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name></person-group><year>2002</year><article-title>Power and sample size calculations for case-control genetic association tests when errors present: application to single nucleotide polymorphisms.</article-title><source>Human Heredity</source><volume>54</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">12446984</pub-id></citation></ref><ref id="pone.0005168-Nielsen1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>DM</given-names></name><name><surname>Ehm</surname><given-names>MG</given-names></name><name><surname>Weir</surname><given-names>BS</given-names></name></person-group><year>1998</year><article-title>Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus.</article-title><source>Am J Hum Genet</source><volume>63</volume><fpage>1531</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">9867708</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>Indian Council of Medical Research (ICMR) provided research fellowship to TSA and TSR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 